相关实验视频

Updated: Jan 7, 2026

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Published on: December 21, 2019

基于结构的虚拟查KHK-A抑制剂与抗肝细胞癌活性

Jiang-Yi Zhu¹, Xiao-Yang Han², Zi-Ying Zhou¹

¹Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.

Pharmaceuticals (Basel, Switzerland)

|December 31, 2025

概括

研究人员确定了HK-4,一种小分子,通过向KHK-A来抑制肝细胞癌 (HCC) 的生长. 这一发现为HCC提供了一种新的治疗策略,HCC是一种常见的,往往致命的癌症.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药物发现药物发现药物发现

背景情况:

肝细胞癌 (HCC) 是一种普遍存在的恶性瘤,结果不佳.
氧化应激显著促进HCC的发展和进展.
氧化应激途径中的一种蛋白质KHK-A与各种癌症有关.

研究的目的:

通过基于结构的虚拟查来识别KHK-A的小分子抑制剂.
评估KHK-A抑制剂对HCC的治疗潜力.
探索KHK-A作为HCC治疗的可行的治疗点.

主要方法:

使用Discovery Studio (DS) 2019对SPECS数据库进行基于结构的虚拟选.
识别潜在的KHK-A抑制剂 (HK1-HK24).
通过分子对接和体外细胞测试来评估抑制剂的疗效.

主要成果:

化合物HK-4显示显著抑制HCC细胞的增殖,迁移和入侵.
在不同的HCC细胞系中,HK-4的IC50值从22.54μM到23.91μM不等.
在PI3K-AKT通路中,HK-4诱导了G1细胞周期停止,促进了细胞亡,并降低了PI3K-AKT通路中的p-AKT和p-mTOR的调节.

结论:

HK-4是一种新的小分子KHK-A抑制剂,具有强大的抗HCC活性.
HK-4的抗癌作用通过调节PI3K-AKT信号通路来调节.
KHK-A代表了开发新的抗HCC药物的有前途的治疗标.

关键词:

一个KHK-A的KHK-A 基于结构的药物设计.虚拟选虚拟选虚拟选

更多相关视频

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology

Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology

Published on: November 22, 2024

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...